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DNA Nanocarriers for Systemic Administration: 
 Characterization and In Vivo Bioimaging in  
Healthy Mice
Stephanie David1–3, Catherine Passirani1,2, Nathalie Carmoy4,5, Marie Morille1,2, Mathieu Mevel3, Benoit Chatin3, Jean-Pierre Benoit1,2, 
Tristan Montier4–6 and Bruno Pitard3,7
We hereby present different DNA nanocarriers consisting of new multimodular systems (MMS), containing the cationic lipid 
dioleylaminesuccinylparomomycin (DNA MMS DOSP), or bis (guanidinium)-tren-cholesterol (DNA MMS BGTC), and DNA lipid 
nanocapsules (DNA LNCs). Active targeting of the asialoglycoprotein receptor (ASGP-R) using galactose as a ligand for DNA 
MMS (GAL DNA MMS) and passive targeting using a polyethylene glycol coating for DNA LNCs (PEG DNA LNCs) should improve 
the properties of these DNA nanocarriers. All systems were characterized via physicochemical methods and the DNA payload 
of DNA LNCs was quantified for the first time. Afterwards, their biodistribution in healthy mice was analyzed after encapsulation 
of a fluorescent dye via in vivo biofluorescence imaging (BFI), revealing various distribution profiles depending on the cationic 
lipid used and their surface characteristics. Furthermore, the two vectors with the best prolonged circulation profile were 
administered twice in healthy mice revealing that the new DNA MMS DOSP vectors showed no toxicity and the same distribution 
profile for both injections, contrary to PEG DNA LNCs which showed a rapid clearance after the second injection, certainly due 
to the accelerated blood clearance phenomenon.
Molecular Therapy–Nucleic Acids (2012) 2, e64; doi:10.1038/mtna.2012.56; published online 8 January 2013
Subject Category: Gene Vectors; Nanoparticles
Introduction
Gene therapy is an emerging technology that aims to perma-
nently or temporarily correct a gene defect by the intracellular 
delivery of nucleic acids.1 Gene defects can either arise dur-
ing cell division processes or be due to external agents (such 
as ultraviolet (UV) or other radiation, chemical substances). 
The introduction of a plasmid DNA, encoding the native form 
of the gene can be a way to conquer these gene defects. 
Since naked plasmid DNA is quickly degraded by blood 
nucleases and in general shows no relevant therapeutic 
effects when administered systemically,1 vectors are neces-
sary to transport plasmid DNA into the cell nucleus. In gen-
eral, as with any drug, gene transfer complexes must reach 
their intended site of action to induce therapeutic effects, but 
this can be compromised through unspecific interactions, 
especially if they are frequently re-administrated. Conse-
quently, one basic challenge for nonviral gene therapy is to 
develop an approach that delivers a therapeutic gene into 
selected cells. With this aim in mind, two different types of 
promising nanocarriers were developed in our laboratories: 
lipid nanocapsules (DNA LNCs) and multimodular systems 
(DNA MMS). DNA LNCs consist of a lipophilic lipid core, con-
taining a mixture of triglycerides and polyglyceryl-6 dioleate 
surrounded by a shell composed of free polyethylene glycol 
(PEG) and hydroxystearate-PEG.2 To encapsulate hydro-
philic DNA in the lipophilic lipid core, the first step consists of 
complexing the anionic DNA with cationic lipids, to form lipo-
plexes which are then introduced into the formulation process 
of DNA LNCs, based on phase-inversions of an emulsion.3 
DNA LNCs encapsulating a luciferase-coding plasmid DNA 
proved their transfection efficacy in vitro4 and, after surface 
coating with DSPE-PEG2000 chains forming PEG DNA LNCs, 
prolonged their circulation in the blood and their transfection 
efficacy in vivo in a tumor model.5,6 DNA MMS also exhibit a 
dual structure: a core composed of lipoplexes and an exter-
nal corona of steric stabilizers capable of carrying the ligands 
necessary for active targeting. The first DNA MMS that 
were developed consisted of the cholesterol derivate BGTC 
(bis-guanidinium-tren-cholesterol) as a cationic lipid, the 
plasmid pCMV luciferase, and the steric stabilizer F108 (a 
block copolymer of poly(ethylene oxide) and poly(propylene 
oxide)), with or without galactose (GAL) as a ligand. They 
had already been tested in vitro on primary hepatocytes7 and 
demonstrated a specific transfection for galactosylated DNA 
MMS due to the recognition of the GAL ligands by ASGP-R, 
present on hepatocytes.
With the aim of developing new, efficient nonviral DNA 
nanocarriers, new MMS containing the aminoglycoside deri-
vate DOSP (dioleylsuccinylparomomycin) were developed 
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and compared with the already in vitro-tested DNA MMS 
BGTC. In parallel, the DNA payload in DNA LNCs was for 
the first time quantified and localized. Afterwards, both DNA 
MMS, in the presence and absence of GAL, as well as DNA 
LNCs and PEG DNA LNCs, were injected for the first time 
via intravenous injection into healthy mice and their different 
biodistribution and kinetics were explored, via noninvasive in 
vivo biofluorescence imaging (BFI).8 Finally, PEG DNA LNCs 
and DNA MMS DOSP, the DNA nanocarriers with the lon-
gest circulation time, were tested for repeated administration 
because in future therapeutic applications multiple injections 
can be envisaged to improve the effect of the plasmid DNA.
Results
DNA nanocarrier characterization
DNA MMS DOSP—new MMS for systemic administration. 
Similar to DNA MMS BGTC, new DNA MMS containing the 
cationic lipid DOSP were developed. They can be recovered 
with GAL in order to target the ASGP-R in future applications 
directed to the liver. To determine their colloidal stability,9 elec-
trophoresis experiments (Figure 1a), size measurements 
(Figure 1b), and fluorescence measurements (data not 
shown) of DOSP/DOPE/DNA lipoplexes were performed at 
different charge ratios (CR), defined as the ratio of the cat-
ionic lipid charge to the anionic nucleic acid charge (+/−).10 
Three zones of colloidal stability A (CR <2), B (CR 2–5), and 
C (CR >5) were determined with a complete complexation 
of the nucleic acids at CR ≥2 indicated by low fluorescence 
intensities in electrophoresis and fluorescence measurements 
(data not shown). As a consequence, CR 2 was chosen, but 
lipoplexes at this CR rate had an increased size and were col-
loidally unstable. To prevent their aggregation due to their neu-
tral surface charge, the polymer F108 was added to efficiently 
reduce their size (final size about 100–130 nm, Figure 1c). In 
addition, for all F108/DNA ratios tested, no fluorescence signal 
was detected in electrophoresis experiments thus indicating 
no dissociation of the lipoplexes ( Figure 1d). In view of these 
results, and in accordance with DNA MMS BGTC, the F108/
DNA and F108-gal/DNA ratio of 300 (wt/wt) was chosen.
DNA LNCs—quantification of the DNA payload. To check 
DNA complexation (lipoplexes) or encapsulation (DNA 
LNCs) and to confirm that the purification and that the post-
insertion process did not modify the DNA encapsulation in 
PEG DNA LNCs, gel electrophoresis experiments were per-
formed. When LNCs were intact, only very low fluorescence 
signals were detected for both types of LNCs, indicating nei-
ther a loss of DNA nor the liberation of DNA from the DNA 
LNCs (Figure 2a). In contrast, after LNC destruction with 
Triton, an intense fluorescence signal was observed in both 
cases. Afterwards, the DNA localization (lipoplexes versus 
LNCs) was determined using a newly developed quantitative 
method based on chloroform extraction and subsequent UV 
spectroscopy analysis at 260 nm. Our hypothesis is that DNA 
could be potentially localized in four different compartments 
of the formulation (Figure 2b): (1) free DNA molecules, (2) 
DNA molecules in lipoplexes outside LNCs, (3) lipoplexes 
encapsulated in LNCs, and (4) DNA molecules encapsulated 
in LNCs dissociated from cationic lipids. DNA quantification, 
before purification or post-insertion (Table 1), revealed about 
16% of free DNA molecules, corresponding to a small line 
of fluorescence at gel electrophoresis experiments, about 
65% in lipoplexes outside DNA LNCs and up to 22% of DNA 
encapsulated in LNCs, whereas the major part was dissoci-
ated from cationic lipids (21 versus 1%). The experimental 
DNA payload was about 0.07% compared with the theoretical 
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Figure 1 Development of DNA MMS DOSP. (a) Electrophoresis experiments and (b) size measurements were performed at different 
charge ratios (CR) of DOSP/DOPE/DNA lipoplexes to determine their colloidal stability. (c) Size measurements and (d) electrophoresis 
experiments of DOSP/DOPE/DNA lipoplexes at CR 2 with different polymer/DNA ratios were performed to determine the quantity of polymer 
used for DNA MMS DOSP. Ctrl, control; DOPE, 1,2-dioleyl-sn-glycero-3-phosphoethanolamine; DOSP, dioleylsuccinylparomomycin; MMS, 
multimodular system.
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DNA payload of 0.29%. To eliminate free DNA, DNA LNCs 
were purified by gel chromatography before being coated 
with PEG and used for in vivo experiments. Due to the similar 
size between DNA LNCs and DNA lipoplexes, we hypoth-
esized that these last particles were not totally eliminated by 
chromatography columns. Consequently, DNA LNCs or PEG 
DNA LNCs used for the different experiments likely corre-
sponded to a mixture of DNA lipoplexes and LNC. To ensure 
the homogen composition from batch to batch (size, zeta 
potential, and DNA payload), all preparations were charac-
terized by physicochemical methods before use for further 
experiments.
Physicochemical characterization of the different DNA nano-
carriers. The lipoplex composition used for DNA LNCs, PEG 
DNA LNCs, DNA MMS BGTC, GAL DNA MMS BGTC and 
the newly developed DNA MMS DOSP and GAL DNA MMS 
DOSP, as well as the polymer/DNA ratios used for in vivo 
experiments are listed in Table 2. The plasmid luciferase was 
initially chosen as a model because it can be quantified quite 
easily. Before using these DNA nanocarriers for in vivo exper-
iments, they were characterized by size and zeta potential 
measurements (Table 2). DNA LNCs had a size of 114 nm 
with a polydispersity index of 0.3 and a positive zeta potential 
of +27 mV. Coating the surface with DSPE-PEG2000 resulted 
in a size of 132 nm and a negative zeta potential of −17 mV 
due to dipolar interactions of PEG with water as previously 
described.11 DNA MMS showed sizes of 150 nm (BGTC) and 
200 nm (DOSP) with a polydispersity index of 0.4. The addi-
tion of GAL resulted in a size of 300 nm for GAL DNA MMS 
BGTC, which agrees well with previous results,7 and resulted 
in a size of 150 nm for GAL DNA MMS DOSP with a polydis-
persity index of 0.5 and unchanged neutral zeta potentials.
In vivo BFI in healthy animals
Biodistribution after one systemic administration. For in vivo 
experiments, nude mice were chosen to avoid hair autofluo-
rescence, to facilitate observations by in vivo BFI,12 and to 
compare the results with those previously obtained on dif-
ferent tumor models.5,6,13 To follow the DNA nanocarriers via 
BFI, we used as in a previously reported study5 the fluores-
cent dye, DiD (a near-infrared fluorophore used to avoid the 
autofluorescence wave length emitted by animals) encap-
sulated in the different DNA nanocarriers and images were 
taken 1, 3, 5, and 24 hours after systemic administration 
(Figure 3) from lateral and decubitus dorsal views. Differ-
ent regions of interest were selected to quantify the fluores-
cence intensities: (1) the abdominal region, including liver 
and bladder, (2) bladder, (3) liver, and (4) lungs (Figure 4). 
The DNA MMS BGTC and GAL DNA MMS BGTC were rap-
idly accumulated in the liver. This accumulation persisted 
during the whole observation period and was similar for both 
DNA nanocarriers. From the raw data (data not shown), the 
calculated fluorescence intensities in the liver were three to 
four times higher than in the bladder and about two times 
higher than in the lungs. DNA MMS DOSP showed an accu-
mulation in the liver, but less important than for DNA MMS 
BGTC. A fluorescence signal was also observed in the uri-
nary system, and in the lungs during the whole period with 
similar intensities than in liver and bladder. Interestingly, 
DNA MMS DOSP had an increased circulation time com-
pared with the other DNA MMS tested, with fluorescence 
signals four to five times higher than for GAL DNA MMS 
DOSP and an increase at 24 hours. The addition of GAL 
ligands to these systems provided an accentuated accu-
mulation in the liver with less accumulation in the urinary 
system and the lungs than for DNA MMS DOSP. The fluo-
rescence intensities in the liver were two times higher than 
in the bladder and about one-third than that of the lungs. 
DNA LNCs showed a wide degree of distribution 1 hour after 
intravenous administration, with fluorescence intensities in 
the liver and the lungs about two times higher than in the 
bladder. Afterwards, a rapid and important decrease of the 
fluorescence signal was observed as the signal was divided 
by two at 3 hours compared with 1 hour. The addition of long 
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Figure 2 DNA quantification in DNA LNCs. (a) Electrophoresis 
experiments were performed to check DNA encapsulation in DNA 
LNCs and PEG DNA LNCs. (b) Schematic representation of DNA 
localization in the DNA LNC formulation (1) as free DNA, (2) in 
lipoplexes outside LNCs, (3) in lipoplexes inside LNCs or (4) in 
LNCs dissociated from cationic lipids. LNC, lipid nanocapsule; PEG, 
polyethylene glycol.
Table 1 DNA quantification in three different formulations before purification and post-insertion with DSPE-PEG
(1) Free DNA  
(%)
(2) Free  lipoplexes 
(%)
(3) Encapsulated 
 lipoplexes (%)
(4) Encapsulated  
DNA (%)
DNA in LNCs (%) 
(3 + 4)
DNA  payloada  
(%)
Formulation 1 0 85 ± 4 1 ± 1 15 ± 6 16 ± 4 0.05 ± 0.01
Formulation 2 21 ± 20 56 ± 34 6 ± 8 21 ± 21 27 ± 14 0.09 ± 0.06
Formulation 3 27 ± 5 53 ± 1 0 21 ± 4 21 ± 4 0.07 ± 0.02
Mean 16 ± 14 65 ± 18 1 ± 2 21 ± 5 22 ± 5 0.07 ± 0.02
LNC, lipid nanocapsule; PEG, polyethylene glycol.
aExperimental DNA payload (%) calculated as wt (DNA in LNCs)/wt (formulation) × 100.
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DSPE-PEG chains augmented the circulation time up to 5 
hours after administration with a maximal signal at 3 hours 
and showed a wide distribution in the whole body as with 
DNA LNCs at 1 hour. However, 24 hours after their adminis-
tration, no fluorescence was detected on the images as the 
fluorescence signal was only about 60% of the initial signal, 
indicating the elimination of these systems.
Biodistribution after repeated administration. As the repeated 
administration of these systems could be envisaged in a 
treatment context (chronic disease), the two systems with the 
longest circulation profile (PEG DNA LNCs and DNA MMS 
DOSP) were followed via BFI after two intravenous injections 
administered at time intervals of 1 week (Figures 4d and 5). 
Images of the first injection have already been described in 
the previous section. After the second injection of DNA MMS 
DOSP, the biodistribution profile was similar to the first one, 
represented by a prolonged circulation time and an increase 
of the fluorescence signal at 24 hours. However, the fluores-
cence signals in the liver and in the lungs were, that time, 
twice higher than in the bladder, like for DNA LNCs. The 
biodistribution profile for the PEG DNA LNCs after the sec-
ond injection showed a reduced circulation time and a similar 
profile to DNA LNCs, with wide distribution in the whole body 
1 hour after administration. In contrast, an augmentation of 
the signal in the lungs and the liver to 2.5 times than that in 
the bladder after the second injection and a high level of intol-
erance to PEG DNA LNCs after the second injection were 
observed.
Hepatotoxicity of PEG DNA LNCs and DNA MMS DOSP. To 
determine the hepatotoxicity of PEG DNA LNCs and DNA 
MMS DOSP, blood samples were collected regularly during 
the observation period and the enzyme activity of alanine 
aminotransferase (ALAT) and aspartate aminotransferase 
(ASAT) were quantified (Figure 6) indicating a hepato-
toxicity when both ALAT values, specific to the liver, and 
ASAT values, also found in other organs and tissues, were 
increased. For the group receiving PEG DNA LNCs, ASAT 
and ALAT values showed a slight increase 24 hours after the 
first injection. These values increased again, but to a lesser 
extent, 24 hours after the second injection. However, these 
values are near to the values obtained for the control group 
Table 2 Characteristics of the different DNA nanocarriers encapsulating the plasmid pGWIZ-luciferase
DNA nanocarrier specifications
DNA LNCs PEG DNA LNCs
DNA MMS  
BGTC
GAL DNA  
MMS BGTC
DNA MMS  
DOSP
GAL DNA  
MMS DOSP
Lipoplex composition
Lipids DOTAP/DOPE DOTAP/DOPE BGTC/DOPE BGTC/DOPE DOSP/DOPE DOSP/DOPE
Charge ratio 5 5 2 2 2 2
Polymer composition
Polymer — DSPE-PEG2000 F108 F108-gal F108 F108-gal
Ratio polymer/DNA (wt/wt) — 70 300 300 300 300
Size (nm) 114 ± 25 132 ± 3 150 ± 32 298 ± 171 198 ± 57 152 ± 58
PDI 0.3 0.3 0.4 0.5 0.4 0.5
Zeta potential (mV) 27 ± 12 −17 ± 4 −3 ± 2 −2 ± 1 0 −2 ± 0
BGTC, bis (guanidinium)-tren-cholesterol; DOPE, 1,2-dioleyl-sn-glycero-3-phosphoethanolamine; DOSP, dioleylsuccinylparomomycin; DOTAP, 1,2- 
dioleyl-3-trimethylammoniumpropane; GAL, galactose; LNC, lipid nanocapsule; MMS, multimodular system; PDI, polydispersity index; PEG, polyethylene glycol.
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Figure 3 BFI of the different DNA nanocarriers administered 
via intravenous injection in healthy animals at different 
times. DNA MMS BGTC, GAL DNA MMS BGTC, DNA MMS 
DOSP, GAL DNA MMS DOSP, DNA LNCs, and PEG DNA LNCs 
encapsulating a fluorescent tracer, DiD, were injected intravenously 
in healthy mice (two animals per group) and BFI images were 
taken at different times (1, 3, 5, and 24 hours after injection) from 
decubitus dorsal (first line) and lateral (second line) views to follow 
their biodistribution. BFI, biofluorescence imaging; BGTC, bis 
(guanidinium)-tren-cholesterol; DOSP, dioleylsuccinylparomomycin; 
GAL, galactose; LNC, lipid nanocapsule; MMS, multimodular 
system; PEG, polyethylene glycol.
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Figure 4 Fluorescence quantification after systemic administration of the different DNA nanocarriers in healthy mice. Different 
regions of interest were selected to quantify the fluorescence signal from images taken via BFI (Figures 3 and 5) at different times (1, 3, 5, 
and 24 hours after the first injection, or 0 (before), 1, 3, 5, and 24 hours after the second injection) (two animals per group): (1) the abdominal 
region, including liver and bladder, (2) bladder, (3) liver, and (4) lungs. Values were normalized with the values of control animals (receiving 
no injection). (a) Animals receiving one injection of DNA MMS BGTC or GAL DNA MMS BGTC, (b) animals after one injection of DNA MMS 
DOSP or GAL DNA MMS DOSP, (c) animals after one injection of DNA LNCs or PEG DNA LNCs, and (d) animals after two injections of DNA 
MMS DOSP or PEG DNA LNCs. BFI, biofluorescence imaging; BGTC, bis (guanidinium)-tren-cholesterol; DOSP, dioleylsuccinylparomomycin; 
GAL, galactose; LNC, lipid nanocapsule; MMS, multimodular system; PEG, polyethylene glycol.
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(without nanocarrier injection). ASAT and ALAT values for 
the mice receiving DNA MMS DOSP, showed nearly the 
same profile as the ASAT and ALAT values for the  control 
group indicating no hepatotoxicity of these DNA MMS.
Fluorescence accumulation and luciferase quantification in 
different organs 24 hours after intravenous injection. Twenty-
four hours after the last administration of DNA nanocarriers 
(two administrations for PEG DNA LNCs and DNA MMS 
DOSP; one administration for DNA LNCs, DNA MMS BGTC, 
GAL DNA MMS BGTC, and GAL DNA MMS DOSP; and no 
injection for the control group), the animals were killed and 
the fluorescence localization was determined in different 
organs (liver, lungs, kidneys, spleen, and heart) to confirm 
BF images since BFI is affected by tissue depth8 (Figure 7). 
For all DNA nanocarriers, the major intensity was observed 
in the liver, followed by some fluorescence in the lungs and 
almost no fluorescence intensity in the heart, the spleen, 
and the kidneys. In mice receiving the two injections, the 
luciferase expression was also quantified but revealed little 
luciferase expression (<2 relative luciferase unit/mg proteins) 
(data not shown).
Discussion
New MMS containing the lipids DOSP/DOPE (1,2-dioleyl-sn-
glycero-3-phosphoethanolamine) were developed showing 
comparable physicochemical characteristics as previously 
described for DNA MMS BGTC. In parallel, DNA was quanti-
fied and localized for the first time using a method based on 
chloroform extraction and spectroscopy analysis and revealed 
about 22% of DNA being encapsulated in LNCs. The major 
part of this DNA was dissociated from cationic lipids, cer-
tainly due to a rearrangement of the different lipids around 
the nucleic acids during the formulation process, since lipo-
plexes with an initial size of about 400 nm were encapsulated 
in DNA LNCs presenting a size of about 100 nm.2 However, 
a large part of the DNA was still complexed in lipoplexes 
outside DNA LNCs which remained in the formulation even 
after the purification step, carried out to eliminate the excess 
of free components, since they both have similar sizes. This 
was also confirmed by electrophoresis analysis that, showed 
similar fluorescence intensities for DNA LNCs (before the 
purification step) and PEG DNA LNCs (after the purification 
step) (Figure 2a). Most of these (PEG) DNA LNCs and DNA 
MMS, developed in our laboratories, presented appropriate 
characteristics for systemic administration.
In vivo BFI, a fast, simple, and relatively low-cost technique,14 
was used to determine the biodistribution profiles of the DNA 
nanocarriers in healthy mice. With this aim in mind, the fluo-
rescent tracer, DiD, which is not soluble in water and is known 
to be prone to aggregation and auto-quenching in aqueous 
buffer,15 was encapsulated in DNA nanocarriers, which mim-
icked an “organic-like” medium, and thus improved its opti-
cal properties. However, the fluorescence intensity is not an 
absolutely quantitative method and depends on the tissue 
observed and its localization.16 Furthermore, the quantity of 
DiD was not equal in all systems, but quantities in DNA MMS 
with the different lipids and ligands were equal, so they could 
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Figure 5 BFI of DNA nanocarriers in healthy animals after 
repeated, systemic administration. PEG DNA LNCs and DNA 
MMS DOSP encapsulating the fluorescent dye DiD were injected 
twice intravenously in healthy animals with a time interval of 1 
week between administrations and BFI images were taken (from 
two animals per group) at different times (1, 3, 5, and 24 hours 
after each injection and 1 day before the second injection (0 hour)) 
from decubitus dorsal (first line) and lateral (second line) views to 
follow their biodistribution. BFI, biofluorescence imaging; DOSP, 
dioleylsuccinylparomomycin; LNC, lipid nanocapsule; MMS, 
multimodular system; PEG, polyethylene glycol.
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Figure 6 ALAT and ASAT quantification to determine 
hepatotoxicity of PEG DNA LNCs and DNA MMS DOSP. Blood 
samples of animals receiving no injection (control, closed diamonds), 
PEG DNA LNCs (closed triangles) or DNA MMS DOSP (closed 
circles) were collected once a day during the observation period, 
starting 1 hour before the injection of the DNA nanocarriers, to 
analyze the hepatotoxicity of these DNA nanocarriers, represented 
by ALAT (continuous lines) and ASAT values (dashed lines) (n 
= 2 for untreated animals and n = 5 for treated animals). ALAT, 
alanine aminotransferase; ASAT, aspartate aminotransferase; 
DOSP, dioleylsuccinylparomomycin; LNC, lipid nanocapsule; MMS, 
multimodular system; PEG, polyethylene glycol.
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be compared on the one side, and quantities in DNA LNCs and 
PEG DNA LNCs on the other side, were also equal and could 
thus also be compared with each other. Each DNA nanocar-
rier showed a specific biodistribution profile in function of its 
composition. DNA MMS composed of the cationic lipid BGTC 
had a short circulation time and accumulated preferentially in 
the liver whereas DNA MMS composed of the cationic lipid 
DOSP favored prolonged circulation time, as evidenced by a 
clear visible accumulation up to 24 hours after the first injec-
tion. The addition of the ligand GAL to both systems resulted 
in an accumulation in the liver. This phenomenon is certainly 
due to the ASGP-R situated on hepatocytes which recognizes 
terminal, GAL-bearing ASGP and favors the specific internal-
ization of GAL-containing systems.7,17,18 DNA LNCs showed 
wide distribution but a short circulation time which could be 
increased by being coated with DSPE-PEG chains, as has 
also been seen previously on different tumor models.5,6,13
Afterwards, the DNA MMS DOSP and PEG DNA LNC sys-
tems which had the longest circulation times were chosen 
for repeated administration on healthy animals. DNA MMS 
DOSP showed no hepatotoxicity and similar biodistribution 
profiles for both injections. Interestingly, the fluorescence sig-
nal of these systems augmented, contrary to than of the other 
systems, at 24 hours for both injections. This could be due to 
Figure 7 BFI of DNA nanocarriers in different organs 24 hours after the last systemic administration. Animals were killed 24 
hours after the last injection of DNA nanocarriers and the fluorescence intensity in (1) liver, (2) lungs, (3 and 4) kidneys, (5) heart, and (6) 
spleen were measured via BFI. All images were taken with the same settings. (a) Control animals receiving no injection (n = 2), (b) animals 
receiving one DNA MMS BGTC injection (n = 2) (left) or one GAL DNA MMS BGTC injection (n = 2) (right), (c) animals receiving two DNA 
MMS DOSP injections (n = 3) (left) or one GAL DNA MMS DOSP injection (n = 2) (right), (d) animals receiving one DNA LNC injection 
(n = 2) (left) or two PEG DNA LNC injections (n = 4) (right). BFI, biofluorescence imaging; BGTC, bis (guanidinium)-tren-cholesterol; DOSP, 
dioleylsuccinylparomomycin; GAL, galactose; LNC, lipid nanocapsule; MMS, multimodular system; PEG, polyethylene glycol.
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a re-distribution or re-metabolization of the labeled lipid, but 
as it was only observed with these systems, it is likely that 
this phenomenon could be attributed to the DNA complexes 
rather than the tracer itself. In contrast, PEG DNA LNCs were 
rapidly eliminated and showed an augmented intolerance on 
healthy mice after the second injection. The elimination pro-
cess is probably due by the mononuclear phagocyte system,5 
as these DNA nanocarriers are too big for renal elimination 
that is extremely size restricted.19 The fluorescence signal 
observed in the bladder is likely due to the biodegradation of 
the systems occurring inevitably with time after their injection. 
Mice presented signs of paralysis at their extremities and dif-
ficulty in breathing, typical of a shock response, to the point of 
rapid mortality within 10–30 minutes after the injection of some 
animals. This could be due to the accelerated blood clearance 
phenomenon of the PEGylated carriers in combination with 
their inflammatory payload (plasmid DNA) and the use of athy-
mic (nude) mice. This phenomenon has already been reported 
in the literature20–22 but is still not fully elucidated. Two distinct 
phases can be determined in this phenomenon.23,24 (i) The 
induction phase following the first injection, where liposomes, 
or in our case PEG DNA LNCs, bind and cross-link surface 
immunoglobulin on PEG-reactive B-cells,25 inducing the pro-
duction of anti-PEG IgM and (ii) the effectuation phase follow-
ing the second injection, whereas on the one hand, the DNA 
payload is internalized followed by B-cell stimulatory pathway 
activation, such as TLR 926 and on the other hand, acces-
sory cells are induced to produce cytokines, independent of 
T helper cell26–28 followed by the rapid clearance of the PEGy-
lated carriers from the bloodstream, mainly by Kupffer cells 
in the liver. The severe reactions observed here, including the 
death of some mice, could be due to the non-regulation of the 
immune response due to the use of nude (athymic) mice,22,29,30 
but the regulation is complex and needs further investigations 
to be fully understood.
For the long-circulating systems, PEG DNA LNCs and 
DNA MMS DOSP, no luciferase or very low expression 
could be detected 24 hours after the last injection in any 
organ although fluorescence was observed in the liver. This 
is in good agreement with our object whether to transfect 
only deficient cells and no healthy cells. To obtain transfec-
tion, a targeting strategy is necessary as was observed in 
other in vivo studies with grafted tumors after intravenous 
injection of PEG DNA LNCs (passive targeting)6 and GAL 
DNA MMS DOSP (active targeting).31 
The absence of transfection in the physiological liver, 
observed here, could suggest that the number of hepatocytes 
transfected by nanoparticles compared with the total number of 
hepatocytes is not sufficient to produce enough luciferase to be 
detected. In contrast, by using targeting strategies, as was done 
in the other studies, accumulated doses were probably greater 
which led to more efficient transfection. For PEG DNA LNCs, 
an important point for the absence of luciferase expression is 
certainly the rapid clearance of these DNA nanocarriers after 
the second injection due to the accelerated blood clearance 
phenomenon. For the future, there are different possibilities to 
diminish this immunogenic response by considering the time 
interval between the different injections,21,32 the lipid composi-
tion of the PEG component,21,33 the sequence of the pDNA,22 
and/or the animals20 used.
In summary, we have presented here various DNA nano-
carriers for systemic administration with appropriate physi-
cochemical properties and different biodistribution profiles 
depending on their lipid and surface composition. These DNA 
nanocarriers represent a promising tool for various applica-
tions such as tumor targeting or hepatocyte targeting. Further-
more, this platform can easily be complemented using other 
lipids and/or ligands.
Materials and Methods
DNA nanocarrier preparations. All DNA nanocarriers used 
were based on lipoplex formation prepared by adding equal 
volumes of DNA plasmid (pgWIZ-luciferase (Gene Therapy 
systems, San Diego, CA)) and liposomes in a defined CR of 
cationic lipid charge and anionic DNA charge to obtain a final 
DNA concentration of 0.25 g/l for DNA MMS or 0.825 g/l for 
DNA LNCs. NaCl was added during preparation, to obtain a 
final concentration of 0.15 mol/l. Lipoplexes were incubated 
for 20 minutes at room temperature before use. For lipo-
some preparation, a cationic lipid DOSP (synthesis previously 
described in ref. [34]), BGTC (synthesis previously described in 
ref. [35]) or DOTAP (1,2-dioleyl-3-trimethylammoniumpropane) 
(Avanti Polar Lipids, Alabaster, AL) was weighted with the neu-
tral lipid DOPE (Avanti Polar Lipids) at the ratios 1/1, 3/2, and 
1/1 (mol/mol), respectively to obtain a final concentration of 
20 mmol/l of cationic lipid charge (considering the number of 
positive charges per molecule: 4 for DOSP, 2 for BGTC, and 
1 for DOTAP), and solubilized in chloroform. Chloroform was 
then evaporated under vacuum to obtain a homogeneous lipid 
film which was hydrated with deionized water overnight at 4 °C. 
The next day, liposomes were sonicated and size measure-
ment was performed before use. To prepare DNA MMS for BFI, 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine per-
chlorate (DiD, emission = 644 nm; excitation = 665 nm) (Invit-
rogen, Cergy-Pontoise, France) was added to the lipids before 
lipid film preparation and the steric stabilizers F108 (80% 
poly(ethylene oxide), molecular weight 14,600, generously pro-
vided by BASF, Ludwigshafen, Germany) or F108-gal (synthe-
sis previously described in ref. [7]) were added to DOSP/DOPE 
or BGTC/DOPE liposomes before lipoplex preparation. To 
obtain fluorescent DNA LNCs for BFI, DOTAP/DOPE/DNA lipo-
plexes (CR = 5), corresponding to 78.9% (wt/wt), were added 
to 9.9% (wt/wt) lipophilic Labrafac WL 1349 (Gatefossé S.A., 
Saint-Priest, France) mixed with DiD as described in ref. [36], 
3.9% (wt/wt) oleic Plurol (Polyglyceryl-6 dioleate) which was 
kindly provided by Gatefossé S.A., 1.4% (wt/wt) NaCl (Prolabo, 
Fontenay-sous-Bois, France), and 5.9% (wt/wt) Solutol HS-15 
(BASF).3 Briefly, after mixing all the components, temperature 
cycles around the phase-inversion temperature were performed 
under magnetic stirring. Later, ice-cooled water (obtained from 
a Milli-Q-plus system; Millipore, Paris, France) was added (at a 
ratio of 1:1.96) to dilute the obtained microemulsion and form 
LNCs. To eliminate free components, DNA LNCs were puri-
fied, using PD10 Sephadex columns (Amersham Biosciences 
Europe, Orsay, France), ultrafiltrated with MilliporeAmicon 
Ultra-15 centrifugal filter devices (Millipore, St Quentin-Yve-
lines, France) and then the salt and LNC concentrations were 
readjusted to obtain a physiologic concentration of NaCl (150 
mmol/l) and the initial concentration of LNCs (152 g/l).2 PEG 
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DNA LNCs with a final polymer concentration of 10 mmol/l were 
obtained by a post-insertion process which consisted of mixing 
purified DNA LNCs with DSPE-mPEG2000 (1,2-DiStearoyl-sn-
glycero-3-PhosphoEthanolamine-N-[methoxy (polyethylene 
glycol)-2000], mean molecular weight = 2,805 g/mol; Avanti 
Polar Lipids), and an incubation for 4 hours at 30 °C by vortex-
ing every 15 minutes.5
DNA nanocarrier characterization
Size and zeta potential measurements. Size measurements 
for DNA MMS DOSP development described in the first sec-
tion of the results were performed using a Malvern Zetasizer 
300HSA (Malvern Instruments S.A., Worcestershire, UK) 
with a dilution of 4:100 in 0.15 mol/l NaCl. Size and zeta 
potential measurements for DNA nanocarrier characteriza-
tion were performed using a Malvern Zetasizer (Nano Series 
ZS; Malvern Instruments S.A.) at 25 °C, in triplicate after dilu-
tion at a ratio of 1:100 with deionized water for DNA LNCs or 
at a ratio of 4:100 with 0.15 mol/l NaCl for DNA MMS DOSP.
Agarose gel electrophoresis. Sample preparation for electro-
phoresis experiments with the aim of DNA MMS DOSP develop-
ment, described in the first section of the results, was performed 
by mixing complexes with Orange Blue loading dye (Promega, 
Madison, WI). In contrast, a sample preparation for electropho-
resis experiments with (PEG) DNA LNC formulations was per-
formed as previously described.2 Briefly, a treatment with Triton 
X100 (Sigma, Saint-Quentin Fallavier, France) was performed 
to destroy a volume of LNCs equivalent to 0.2 μg of DNA and 
samples with or without treatment were mixed with gel-loading 
solution (Sigma). In both cases, the prepared samples were 
then deposited on 1% agarose gel containing ethidium bromide 
(Sigma) to migrate for about 30 minutes at 100 V.
DNA quantification in DNA LNCs. To analyze the free and 
encapsulated DNA quantity in DNA LNCs, a volume of DNA 
LNCs was mixed with four volumes of water (obtained from 
a Milli-Q-plus system; Millipore) and one volume of chloro-
form, vortexed and immediately centrifuged for 15 minutes 
at 12,600 rpm at 4 °C. The aqueous phase, containing free 
DNA, was removed and analyzed with a UV spectropho-
tometer (UVIKON 922; Kontron Instruments, Munic, Ger-
many) at 260 nm. The volume removed for quantifying the 
free DNA was replaced by pure ethanol, to liberate the DNA 
encapsulated in the DNA LNCs, and six volumes of water 
were added before vortexing and immediately centrifuging 
a second time for 15 minutes at 12,600 rpm at 4 °C. The 
aqueous phase, containing the liberated DNA from DNA 
LNCs, was removed and analyzed as previously with a UV 
spectrophotometer (UVIKON 922; Kontron Instruments) 
at 260 nm. To analyze the DNA quantity complexed with 
cationic lipids inside or outside the DNA LNCs, the same 
procedure was used, but water was replaced by 1 mol/l of 
NaOH to dissociate the lipoplexes. The first aqueous phase 
contained the DNA liberated from lipoplexes outside DNA 
LNCs; the second aqueous phase contained the DNA liber-
ated from lipoplexes inside DNA LNCs. The DNA quantity 
was calculated using a calibrating curve with different DNA 
concentrations and compared with the total DNA amount 
encapsulated in theory in DNA LNCs.
In vivo experiments
DNA nanocarrier administration. Six- to nine-weeks-old 
female, nude SWISS mice (Charles River, L’Arbresle, France) 
were housed and maintained at the University animal facility; 
they were processed in accordance with the Laboratory Ani-
mal Care Guidelines (NIH Publication 85-23, revised 1985) 
and with the agreement of the regional veterinary services 
(authorization FR; 29-024). The different nanocarriers were 
injected at volumes of 150 μl for DNA LNCs and PEG DNA 
LNCs, and 200 μl for DNA MMS, by intravenous injection into 
the tail vein of the mice. Animals receiving PEG DNA LNCs 
and DNA MMS DOSP were injected twice at a time interval 
of 1 week between the two injections. The animals were killed 
24 hours after the last intravenous injection.
In vivo BFI. To follow the biodistribution of the different 
nanocarriers, noninvasive fluorescent imaging (BFI) was 
performed 1, 3, 5, and 24 hours post-injection as described 
before on two animals per group.13 Briefly, the BFI system 
of the NightOWL II (Berthold Technologies, Stuttgart, Ger-
many) equipped with a cooled, slow-scan CCD camera and 
driven with the WinLight 32 software (Berthold Technolo-
gies) was used, using the 590 nm excitation and 655 nm 
emission filters. Each mouse was anesthetized with isoflu-
rane during the acquisition time (3 seconds for one fluores-
cent acquisition). The fluorescent signal was then quantified 
and overlaid on a picture of each mouse.
Fluorescence and luciferase quantification in different organs. 
Twenty-four hours after the last DNA nanocarrier injection, 
animals were killed and the heart, lungs, spleen, liver, and 
kidneys were dissected. Organs from animals receiving no or 
one DNA nanocarrier injection (two animals per group) and 
organs from half of the animals receiving two DNA nanocarrier 
injections (three animals for the PEG DNA LNCs group and 
four animals for the DNA MMS DOSP group) were immedi-
ately placed in the BFI system and biofluorescence images 
were taken using the same settings as for the whole animals. 
Organs from the other half of the animals receiving two injec-
tions (four animals for the PEG DNA LNCs group and five ani-
mals for the DNA MMS DOSP group) were placed in tubes 
with PLB 1x (Passive Lysis Buffer; Promega France, Lyon, 
France) and shred with the gentleMACS Dissociator (Miltenyi 
Biotec, B ergisch Gladbach, Germany) for luciferase quantifi-
cation. Tubes were centrifuged for 10 minutes at 1,150g at 4 
°C and the upper phase was transferred into Eppendorf tubes. 
After another centrifugation of 10 minutes at 20,000g at 4 °C, 
25 μl of the upper phase was placed, in triplicate, in a white, 
96-well plate and the quantification with the luciferin reagent 
(Promega France) was performed with the MLX luminometer 
plate reader (Dynex, Guyancourt, France).
ALAT—ASAT determination. Blood samples were collected 
from the lateral saphenous vein as described in ref. [37] from 
animals receiving no injections (n = 4), PEG DNA LNCs 
(n = 9), and DNA MMS DOSP (n = 9). Blood was collected 
once a day during the analyzing period on different animals 
(two untreated animals and five treated animals per day) 
to prevent a too great loss of blood, and were collected in 
Microvette collection tubes (Sarstedt, Numbrecht, Germany). 
Afterwards, the samples were centrifuged for 2 minutes at 
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10,000g at 4 °C and the plasma removed for further analysis. 
ALAT and ASAT values were determined using a Selectra-E 
(Elitech, Signes, France).
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